Sullivan Lara 4
4 · Pyxis Oncology, Inc. · Filed Mar 28, 2024
Insider Transaction Report
Form 4
Sullivan Lara
DirectorPresident ,CEO & CMO
Transactions
- Award
Stock Option (Right to Buy)
2024-03-26$3.83/sh+1,071,242$4,102,857→ 1,071,242 totalExercise: $3.83Exp: 2034-03-26→ Common Stock (1,071,242 underlying)
Footnotes (1)
- [F1]The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 26, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.